openPR Logo
Press release

Viral Conjunctivitis Pipeline Drugs Market : Analysis & Trends 2023

04-28-2017 09:55 PM CET | Health & Medicine

Press release from: Transparency Market Research - Pharmaceutical

Viral Conjunctivitis Pipeline Drugs Market : Analysis & Trends

Global Viral Conjunctivitis Pipeline Drugs Market: Overview

Viral conjunctivitis, or “pink-eye”, is a highly contagious infection of the eye, wherein irritation, redness, watery discharge, and photophobia or light sensitivity are common symptoms. Currently, there is no approved treatment for this disease. Therefore, the use of viral conjunctivitis drugs is increasingly becoming mainstream, opening up a broad avenue for these medications. The market for viral conjunctivitis drugs will show an exceptional CAGR of 69.60% during the forecast period 2020-2023, when the projected revenue will reach US$462.4 mn by 2023.

The report furnishes a combined analysis of primary and secondary research gathered from multiple sources, along with the projected market size for every drug that will be introduced in the market by 2023. The CAGR for every segment of the market is revealed. Competition between various existing and viral conjunctivitis drugs, future trends, demographics, epidemiological analysis, regulatory policies, and the overall market landscape have been described extensively. The key catalysts and challenges faced by the global viral conjunctivitis drugs market have been analyzed in the overview section.

The market forecast for the leading countries covers the period from the expected launch up to 2023, together with their respective CAGRs. The report includes significant factors such as the awaited launch date, the number of patients suffering from viral conjunctivitis, and product innovation in each country. The major companies have been profiled in the report, with emphasis on their recent developments, financial overview, business tactics, and product portfolio.

Browse full report on Viral Conjunctivitis Pipeline Drugs Market -
http://www.transparencymarketresearch.com/viral-conjunctivitis-pipeline-drugs-market.html

Global Viral Conjunctivitis Pipeline Drugs Market: Trends and Opportunities

The global viral conjunctivitis drugs market can be broadly categorized according to region and type of drug. FST-100 and APD-209 are the chief drugs in the global viral conjunctivitis drug market. Of these, FST-100 will be more prominent by 2020, suggests TMR. The development of FST-100 was undertaken by a leading drug development company, Foresight Biotherapeutics Inc., which was later acquired by Shire Plc. when the drug was still under development. If approved, the drug will be the premier medication for the treatment of viral and bacterial eye infections, thus promising exhaustive opportunities in the global viral conjunctivitis drugs market.

However, APD-209, though rising in demand at a gradual rate, is likely to witness a higher demand than FST-100. Adenovir Pharma AB has been developing the drug, which is presently in its second stage.

Global Viral Conjunctivitis Pipeline Drugs Market: Regional Outlook

According to regional segmentation, the viral conjunctivitis drugs markets in the U.K., Germany, the U.S., Japan, Brazil, and Australia are evaluated. Owing to the current clinical trials in the U.S., the country is expected to lead the other regions over the coming years. Extensive R&D activities, growing awareness about eye-related diseases, bright prospects of current clinical trials, and the presence of viral conjunctivitis diagnostic tests are few of the many catalysts promoting the U.S. viral conjunctivitis drug market. A favorable CAGR of 46.50% is expected during the forecast period in this regional segment.

Companies Mentioned in the Report

As the demand for viral conjunctivitis drugs is multiplying, major companies are vigorously engaging in research activities so as to bring forth fruitful treatments and diagnostic tests for viral conjunctivitis. The key market players mentioned in the report are Allergan Plc, Panoptes Pharma GES.M.B.H., NovaBay Pharmaceuticals Inc., Shire Plc., NicOx S.A., NanoViricides Inc., and Adenovir Pharma AB.

The viral conjunctivitis drugs market has been segmented as follows:

Viral Conjunctivitis Pipeline Drugs Market, by Drug

FST-100
APD-209
Viral Conjunctivitis Pipeline Drugs Market, by Country

U.S.
U.K.
Germany
Australia
Japan
Brazil
Major regions analyzed under this research report are:

Europe
North America
Asia Pacific
Rest of the World

Request for sample of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12251

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Viral Conjunctivitis Pipeline Drugs Market : Analysis & Trends 2023 here

News-ID: 519517 • Views:

More Releases from Transparency Market Research - Pharmaceutical

Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from 2020 to 2030
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical

All 5 Releases


More Releases for Viral

Viral Inactivation Market Growing Demand of Kits and Reagents Viral Inactivation …
According to Precision Business Insights (PBI), the latest report, the Viral Inactivation market is expected to be worth USD 2.1 billion in 2022, growing at a 12.8% CAGR from 2022 to 2028. The primary driver of the expansion of the global Viral Inactivation market are speedy growth in pharmaceutical and biotechnology industries and strong inclination of R&D investments in life sciences industry. View the detailed report description here - https://precisionbusinessinsights.com/market-reports/viral-inactivation-market/ Kits &
Global Anti-Viral Drug Therapy Market | Global Anti-Viral Drug Therapy Industry …
Anti-viral drug therapy market comprises of sales of branded & generic anti-viral drugs and related services by entities that manufacture the branded or generic anti-viral drugs for treating microbial infections. Anti-viral drug therapy industry includes several establishments that manufacture anti-viral drugs, which are used to treat diseases caused by viral infections. Examples of antiviral drugs include cidofovir, amantadine, zanamivir, idoxuridine, famiciclovir, tenofovir, adefovir and ribavirin. According to study, “Anti-Viral Drug Therapy
Viral Antigens Market to Reap Excessive Revenues by 2028(Based on product type, …
Antigens are commonly referred to as substances that are capable of triggering an immune response in a host by activating the lymphocytes or initiating antibody production against infections. Depending upon the fact that they either enter the human body or originate within the body, viral antigens are classified as foreign or self-antigens respectively. Among these, self-antigens comprise mutated or overexpressed proteins. However, foreign antigens are likely to include bacteria, parasites,
Viral Vector and Plasmid DNA Manufacturing Market - Increase In Awareness Regard …
The Viral Vector and Plasmid DNA Manufacturing Market is expected to reach $ 1,090 million in 2023, growing at an annual average rate of 22.6% from 2017 to 2023. North America was the largest contributor to the viral vector and plasmid DNA markets in 2016. However, the Asia Pacific region is expected to have the highest growth rate during the forecast period. Gene therapy has included tools such as viral vectors
Viral Vaccines Market : Challenges and Opportunities Against Viral Diseases
Vaccines are biotic compositions. They are basically formulated from living beings that increase the resistance against a specific illness. Vaccinations that help in avoiding the occurrence of specific diseases are known as prophylactic vaccines and in other instance, the vaccines that are helpful in treating the disease are called therapeutic vaccines. A vaccine is generally produced by using a weakened or murdered type of the sickness causing microorganism. The agent
Global Viral Molecular Diagnostics Market
The Viral Molecular Diagnostics Market reportprovides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Molecular diagnostics refers to a technique used to detect and identify the presence of genetic material or proteins associated with a specific health condition or disease. Viral molecular diagnostic helps in